肝细胞癌合并门静脉癌栓的治疗现状及进展

Current status and progress of treatment for hepatocellular carcinoma with portal vein tumor thrombus

  • 摘要: 肝细胞癌是全世界第五大常见恶性肿瘤,也是肿瘤导致病人死亡的第二大主要原因,每年新发和死亡病例>50%发生在中国。血管浸润是肝细胞癌的重要生物学特性之一,肝细胞癌合并门静脉癌栓是影响病人预后的重要因素,其治疗方式目前仍存在较大争议。笔者结合国内外相关文献,对肝细胞癌合并门静脉癌栓治疗现状及进展进行综述,探讨其治疗方式。

     

    Abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancers worldwide, which ranks as the second of cancer‑related death. Each year, more than half of the new and death cases occur in China. Vascular invasion is one of the important biological characteristics of HCC. HCC with portal vein tumor thrombus is closely related to the prognosis of patients, but there is no consensus on the best treatment method.Based on domestic and foreign literatures, the authors discuss the current status and progress of treatment for HCC with portal vein tumor thrombus, in order to explore the optimal treatment.

     

/

返回文章
返回